Pfizer击败Q2收入估计数,提出2025年指南,并侧重于主要疗法。 Pfizer beat Q2 earnings estimates, raised 2025 guidance, and focuses on key therapies.

Pfizer报告,在2025年8月5日,Q2收入强劲,收入为78 EPS和146.5亿美元,超过估计数2.0美元,逐年增加10.3%。 Pfizer reported strong Q2 earnings on August 5, 2025, with $0.78 EPS and $14.65 billion in revenue, exceeding estimates by $0.20 and rising 10.3% year-over-year. 该公司将其2025年全年收入指导提高到每股2.90至3.10美元。 The company raised its 2025 full-year earnings guidance to $2.90–$3.10 per share. 机构投资者表现出混合的活跃性,其中Capricorn Fund Managers公司减少了8.5%,Grassi Investment Management公司减少了1.8%,而Stock Yards Bank & Trust增加了551股. Institutional investors showed mixed activity, with Capricorn Fund Managers reducing its stake by 8.5% and Grassi Investment Management cutting its holding by 1.8%, while Stock Yards Bank & Trust increased its position by 551 shares. 股票交易额接近27.37美元,市场上限为155.59亿美元,P/E比率为14.56美元,协商一致的“稳住”评级。 The stock traded near $27.37, with a market cap of $155.59 billion, a P/E ratio of 14.56, and a consensus "Hold" rating. Pfizer继续关注心血管病、传染病和COVID-19治疗,包括科米尔纳蒂、大同协会、Eliquis和Nurtec ODT。 Pfizer continues to focus on cardiovascular, infectious disease, and COVID-19 treatments, including Comirnaty, Paxlovid, Eliquis, and Nurtec ODT.